Market research
PXH.F Pixium Vision SA
F EUR Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 59K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.95
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- FR0011950641
- Market cap
- 59K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.95
About
About Pixium Vision SA
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Research context
Pixium Vision SA appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PXH.F discussion.
5 years, 7 months ago
Pixium Vision SA is currently in a long term downtrend where the price is trading 5.9% below its 200 day moving average.
From a valuation standpoint, the stock is 18.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1077.7.
Pixium Vision SA's total revenue sank by 0.0% to $363K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Pixium Vision SA gets an overall score of 1/5.